ClinicalTrials.gg
RecruitingNCT04774705SNV-SepsisUpdated Jul 17, 2024

Effectiveness of Non-invasive Vagus Nerve Stimulation as an Adjuvant Treatment in Patients With Sepsis in Intensive Care.

An interventional study of SNV activ group (Non-invasive transcutaneous stimulation of the vagus nerve ) and Placebo group in Sepsis and Septic Shock, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-17.

Primary conditionShock, SepticRegistry: SepsisReclassifiedWhy we changed it
Registry
Sepsis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Shock, Septic
Why
  1. The study's listed conditions name Shock, Septic, a narrower term within Sepsis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Mar 2021; still recruiting 5 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris — 15 open to participants now, 16 under way, 3 of them phase 3. Shock, Septic · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
16th of 17
30 · median 210
Started
2021
with 4 others
No phase
8 of 30
5 open now
Primary completion
2025-03
later than 2 of 15 live
Registered
11th of 30
by date

Among the 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris, this one is the 16th largest by planned enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2021, is one of 8 with no phase, reaches primary completion later than 2 of the 15 other live ones, and was the 11th registered.

Shock, Septic

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

Browse Shock, Septic studies →

Open to participants now

15 of the 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 137 Shock, Septic studies recruiting now, 103 (75%) set no upper age limit and 18 (13%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Shock, Septic by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

Sepsis is one of the leading causes of death in intensive care. About 50% of patients with septic shock die after 1 year; and 50% of survivors suffer from cognitive decline. The pathophysiological mechanisms of serious complications of sepsis are now well known. In fact, the systemic inflammation related to sepsis amplifies the release of pro-inflammatory cytokines and neurotoxic mediators, hence an increase in deleterious phenomena such as oxidative stress, mitochondrial dysfunction, endothelial activation, disruption of the blood-brain barrier, neuroinflammation (astrocytic and microglial activation) leading to multi-organ failure which compromises the patient's vital and functional prognosis. Although there has been progress in the understanding of its pathophysiology, the management of sepsis and septic shock in intensive care relies mainly on anti-infective treatments and the restoration of cardiovascular and respiratory functions. There is virtually no adjuvant therapy for the management of sepsis, apart from a few hormonal therapies such as insulin to maintain blood glucose levels below 180 mg / dL and low doses of corticosteroids and vasopressin. There is therefore a pressing need to develop innovative treatments targeting inflammatory and immunological processes in order to reduce the complications of sepsis and improve patient prognosis. Some recent work has shown that electrical vagus nerve stimulation (SNV), a technique used for the treatment of drug-resistant epilepsy, can modulate inflammatory and immune responses and control inflammation syndrome in animal models of sepsis, arthritis and rheumatism in humans. In this pilot study the investigators plan to evaluate the efficacy of transcutaneous (non-invasive) SNV as an adjuvant treatment in patients with sepsis in intensive care.

03

Conditions studied

  • Sepsis
  • Septic Shock

Browse trials for

04

In context

Shock, Septic Reclassified

1,084 studies on the registry are indexed under Shock, Septic; 236 are open to participants now.

This study's planned enrollment of 30 is below the median of 78 across 639 interventional studies indexed under Shock, Septic.

Browse Shock, Septic studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.

Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age> 18 years old
  • Adult man or woman, hospitalized in intensive care, presenting with sepsis for at least 24 hours according to the diagnostic criteria (Singer et al., 2016).
  • signed by patient or family member/trusted support person
  • In an emergency situation, in the absence of family members/trusted family/trusted support person

Exclusion criteria

Exclusion Criteria:

  • Patient under guardianship or curatorship
  • Patient in a severe state of agitation.
  • Patient in a state of brain death or active limitation of treatment.
  • Multiple trauma patient, with multiple fractures of the skull.
  • Refusal to participate in the study or to sign the by the patient or his loved one,
  • Pregnant or breastfeeding woman,
  • No affiliation to a social security scheme.
  • Patient with cochlear implant
  • Patient with heart disease
  • Patient with asthma
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    SNV activ group (Non-invasive transcutaneous stimulation of the vagus nerve )

    Other: SNV activ group (Non-invasive transcutaneous stimulation of the vagus nerve )

  • Placebo comparator
    Control group

    For the SNV placebo group, the stimulation electrode will be inverted so as to deliver the stimulation to the ear lobule.

    Other: Placebo group

Interventions

  • OtherSNV activ group (Non-invasive transcutaneous stimulation of the vagus nerve )

    A transcutaneous stimulator of the atrial branch of the vagus nerve of the TENS eco Plus type (Schwa-medico) will be used. SNV stimulation will be applied in the concha of the left ear to the subcutaneous area of the atrial branch of the vagus nerve in the left ear (cymba conchae) for each patient, at an intensity of 2 mA, 30 minutes per day for 5 consecutive days, from the day of inclusion / randomization.

  • OtherPlacebo group

    For the control group, the stimulation electrode will be inverted so as to deliver the stimulation to the ear lobule.

07

What researchers measure

Primary outcomes

  1. Mortality

    Overall death

    Time frame: at day 90

Secondary outcomes

  1. Cumulative incidence of delirium and its duration

    Time frame: up to day 90

  2. Cumulative incidence of mechanical ventilation and its duration

    Time frame: up to day 90

  3. Proportion of patients having been the subject of a decision to limit or withdraw care

    Time frame: at day 90

  4. Duration of use of vasopressors

    Time frame: at day 90

  5. Number of days alive with a Sequential Organ Failure Assessment Score (SOFA) score <6

    Sequential Organ Failure Assessment Score varies from 0 to 4 and permit to assess organ failure. A higher score indicates better neurological function

    Time frame: at day 90

  6. Length of stay in intensive care and hospitalization in all patients and in survivors

    Time frame: at day 90

  7. Measurements of changes in C-reactive protein (CRP)

    Time frame: at inclusion

  8. Measurements of changes in C-reactive protein (CRP)

    Time frame: at day 7

  9. Measurements of changes in C-reactive protein (CRP)

    Time frame: at day 14

  10. Measurements of changes in C-reactive protein (CRP)

    Time frame: at day 21

  11. Measurements of changes in C-reactive protein (CRP)

    Time frame: at day 28

  12. Measurements of changes in C-reactive protein (CRP)

    Time frame: at day 90

  13. Measurements of changes in fibrinogen level

    Time frame: at inclusion

  14. Measurements of changes in fibrinogen level

    Time frame: at day 7

  15. Measurements of changes in fibrinogen level

    Time frame: at day 14

  16. Measurements of changes in fibrinogen level

    Time frame: at day 21

  17. Measurements of changes in fibrinogen level

    Time frame: at day 28

  18. Measurements of changes in fibrinogen level

    Time frame: at day 90

  19. Measurements of changes in interleukin-6 (IL-6)

    Time frame: at inclusion

  20. Measurements of changes in interleukin-6 (IL-6)

    Time frame: at day 7

  21. Measurements of changes in interleukin-6 (IL-6)

    Time frame: at day 14

  22. Measurements of changes in interleukin-6 (IL-6)

    Time frame: at day 21

  23. Measurements of changes in interleukin-6 (IL-6)

    Time frame: at day 28

  24. Measurements of changes in interleukin-6 (IL-6)

    Time frame: at day 90

  25. Measurements of changes in interleukin-1β (IL-1β)

    Time frame: at inclusion

  26. Measurements of changes in interleukin-1β (IL-1β)

    Time frame: at day 7

  27. Measurements of changes in interleukin-1β (IL-1β)

    Time frame: at day 14

  28. Measurements of changes in interleukin-1β (IL-1β)

    Time frame: at day 21

  29. Measurements of changes in interleukin-1β (IL-1β)

    Time frame: at day 28

  30. Measurements of changes in interleukin-1β (IL-1β)

    Time frame: at day 90

  31. Measurements of changes in tumor necrosis factor α (TNF-α)

    Time frame: at inclusion

  32. Measurements of changes in tumor necrosis factor α (TNF-α)

    Time frame: at day 7

  33. Measurements of changes in tumor necrosis factor α (TNF-α)

    Time frame: at day 14

  34. Measurements of changes in tumor necrosis factor α (TNF-α)

    Time frame: at day 21

  35. Measurements of changes in tumor necrosis factor α (TNF-α)

    Time frame: at day 28

  36. Measurements of changes in tumor necrosis factor α (TNF-α)

    Time frame: at day 90

  37. Measurements of changes in the calcium binding protein B S100B (S100B)

    Time frame: at inclusion

  38. Measurements of changes in the calcium binding protein B S100B (S100B)

    Time frame: at day 7

  39. Measurements of changes in the calcium binding protein B S100B (S100B)

    Time frame: at day 14

  40. Measurements of changes in the calcium binding protein B S100B (S100B)

    Time frame: at day 21

  41. Measurements of changes in the calcium binding protein B S100B (S100B)

    Time frame: at day 28

  42. Measurements of changes in the calcium binding protein B S100B (S100B)

    Time frame: at day 90

  43. Measurements of changes in the arterial lactate level

    Time frame: at inclusion

  44. Measurements of changes in the arterial lactate level

    Time frame: at day 7

  45. Measurements of changes in the arterial lactate level

    Time frame: at day 14

  46. Measurements of changes in the arterial lactate level

    Time frame: at day 21

  47. Measurements of changes in the arterial lactate level

    Time frame: at day 28

  48. Measurements of changes in the arterial lactate level

    Time frame: at day 90

  49. Characteristics of the EEG

    Time frame: at inclusion

  50. Characteristics of the EEG

    Time frame: at day 7

  51. Mortality rate

    Overall death

    Time frame: at day 28

  52. Neurological fate of patients

    Neurological fate of patients will evaluated using Glasgow Outcome Scale (GOS)

    Time frame: at day 90

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2021 (actual). Primary completion is estimated for Mar 2025, 48 months after the start.

Of 165 non-industry interventional studies with no phase under Shock, Septic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 41. This study's planned 48 months is above that.

Counting every sponsor, half of 173 studies reached it within 25 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2021
First posted
Mar 1, 2021
StartActual
Mar 29, 2021
Primary completionEst.
Mar 29, 2025
CompletionEst.
Mar 29, 2025
Last update
Jul 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04774705
Responsible party
Sponsor
First posted
Mar 1, 2021
Start date
Mar 29, 2021
Primary completion
Mar 29, 2025 (estimated)
Completion
Mar 29, 2025 (estimated)
Last update
Jul 17, 2024

Study contacts

Eric AZABOU
Contact
eric.azabou@aphp.fr
+331 47 10 79 40
Matthieu Resche-Rigon
Contact
matthieu.resche-rigon@univ-paris-diderot.fr
+33142499742

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion